Top Dividend Stocks To Invest In Right Now

istar (NYSE:STAR) and Corporate Office Properties Trust (NYSE:OFC) are both finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Volatility & Risk

Get istar alerts:

istar has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Corporate Office Properties Trust has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Dividends

istar pays an annual dividend of $0.36 per share and has a dividend yield of 3.3%. Corporate Office Properties Trust pays an annual dividend of $1.10 per share and has a dividend yield of 3.9%. istar pays out 15.6% of its earnings in the form of a dividend. Corporate Office Properties Trust pays out 54.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Top Dividend Stocks To Invest In Right Now: Dermira, Inc.(DERM)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of skincare pharmaceutical specialist Dermira (NASDAQ:DERM) dropped nearly 23% today after the company hosted its investor and analyst day for 2018. Investors were none too thrilled with the presentations given — and were only reminded about the stinging failure of a once-promising acne drug DRM01 in March. Shares slipped over 64% on that news.

  • [By Chris Lange]

    Dermira Inc. (NASDAQ: DERM) shares made a solid gain to close out the week after the firm announced a key approval from the U.S. Food and Drug Administration (FDA). Essentially, the agency approved Qbrexza (glycopyrronium) cloth.

  • [By Chris Lange]

    Dermira Inc. (NASDAQ: DERM) watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in patients with acne vulgaris. Essentially, Dermira’s Phase 3 trials of the investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints.

  • [By Paul Ausick]

    Dermira Inc. (NASDAQ: DERM) traded down about 64% Monday and posted a new 52-week low of $8.95 after closing Friday at $25.16. The stock’s 52-week high is $38.39. Volume was about 40 times the daily average of around 615,000 shares. The company’s trial of a new acne treatment failed to meet the designated endpoints.

  • [By Stephan Byrd]

    Dermira Inc (NASDAQ:DERM) CEO Thomas G. Wiggans bought 12,000 shares of the business’s stock in a transaction on Monday, July 9th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $120,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

  • [By WWW.GURUFOCUS.COM]

    For the details of Novo A’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Novo+A

    These are the top 5 holdings of Novo AInogen Inc (INGN) – 3,549,320 shares, 59.83% of the total portfolio. Acceleron Pharma Inc (XLRN) – 1,553,937 shares, 9.34% of the total portfolio. Dermira Inc (DERM) – 1,984,364 shares, 7.81% of the total portfolio. Shares added by 3.27%Corvus Pharmaceuticals Inc (CRVS) – 3,244,046 shares, 4.76% of the total portfolio. Akebia Therapeutics Inc (AKBA) – 2,225,000 shares, 4

Top Dividend Stocks To Invest In Right Now: NorthStar Realty Europe Corp.(NRE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Teachers Insurance & Annuity Association of America increased its holdings in NorthStar Realty Europe (NYSE:NRE) by 15.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,499 shares of the financial services provider’s stock after purchasing an additional 9,699 shares during the period. Teachers Insurance & Annuity Association of America owned approximately 0.13% of NorthStar Realty Europe worth $931,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    Northstar Realty Europe Corp (NYSE:NRE) has earned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.83.

  • [By Joseph Griffin]

    Pebblebrook Hotel Trust (NYSE: NRE) and Northstar Realty Europe (NYSE:NRE) are both finance companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

  • [By Jim Royal]

    Investors in NorthStar Realty Europe (NYSE:NRE) woke up to news Tuesday morning that one of the company’s largest investors is looking to shake things up at the company. Senvest Management, which owns 9.55% of NorthStar, is pushing the company’s external advisor, Colony Capital (NYSE:CLNY), to realize value at the undervalued European REIT, after years of a stagnating stock price.

Top Dividend Stocks To Invest In Right Now: Imprimis Pharmaceuticals, Inc.(IMMY)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st
  • [By Stephan Byrd]

    Headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 47.393314841388 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Lisa Levin] Gainers
    Boot Barn Holdings, Inc. (NYSE: BOOT) rose 15.6 percent to $25.40 in pre-market trading after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Abaxis, Inc. (NASDAQ: ABAX) rose 15.3 percent to $82.75 in pre-market trading. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) rose 12.6 percent to $8.95 in pre-market trading after reporting Q1 results.
    Micro Focus International plc (NYSE: MFGP) shares rose 8.8 percent to $18.59 in the pre-market trading session after the company issued strong revenue forecast for the first fiscal half of 2018.
    HC2 Holdings, Inc. (NASDAQ: HCHC) rose 5.6 percent to $6.60 in pre-market trading.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares rose 5.3 percent to $2.79 in pre-market trading. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) rose 5.2 percent to $2.52 in pre-market trading after reporting a first-quarter sales beat.
    Red Violet, Inc. (NASDAQ: RDVT) rose 4.1 percent to $10.35 in pre-market trading after climbing 75.31 percent on Tuesday.
    Xenon Pharmaceuticals Inc (NASDAQ: XENE) rose 3.8 percent to $6.90 in pre-market trading. The stock rose over 10 percent Tuesday after reporting its Phase 1 clinical update on XEN901 demonstrated a favorable PK profile.
    Sea Limited (NYSE: SE) rose 3.5 percent to $11.01 in pre-market trading after reporting Q1 results.
    Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares rose 3.4 percent to $20.98 in pre-market trading after Buffett's Berkshire more than doubled its stake in Teva.
    China Internet Nationwide Financial Services Inc. (NASDAQ: CIFS) shares rose 3.7 percent to $31.30 in pre-market trading after the company reported results for its fourth quarter.
    PetIQ Inc (NASDAQ: PETQ) shares rose 3.4 percent to $20.00 in pre-market t

Leave a Reply

Your email address will not be published. Required fields are marked *